Zeke Capital Advisors’s Blueprint Medicines BPMC Stock Holding History

Zeke Capital Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5,023	Closed	-$254K	–	474
2022 Q2	$254K	Hold	5,023	–	–	0.02%	381
2022 Q1	$321K	Buy	5,023 +1,323	+36%	+$95K	0.02%	352
2021 Q4	$396K	Sell	3,700 -142	-4%	-$14.9K	0.02%	189
2021 Q3	$395K	Hold	3,842	–	–	0.02%	175
2021 Q2	$338K	Buy	3,842 +485	+14%	+$44.4K	0.02%	192
2021 Q1	$326K	Buy	3,357 +1,330	+66%	+$133K	0.02%	191
2020 Q4	$227K	Sell	2,027 -245	-11%	-$25.8K	0.02%	250
2020 Q3	$211K	Buy	+2,272	New	+$175K	0.02%	208
2020 Q1	–	Sell	-9,526	Closed	-$763K	–	274
2019 Q4	$763K	Buy	9,526 +2,288	+32%	+$171K	0.06%	273
2019 Q3	$532K	Buy	7,238 +1,915	+36%	+$166K	0.05%	345
2019 Q2	$502K	Buy	5,323 +1,407	+36%	+$116K	0.05%	355
2019 Q1	$313K	Sell	3,916 -7,998	-67%	-$591K	0.03%	462
2018 Q4	$642K	Buy	11,914 +3,614	+44%	+$220K	0.06%	287
2018 Q3	$648K	Buy	+8,300	New	+$577K	0.05%	334
2018 Q2	–	Sell	-2,253	Closed	-$207K	–	644
2018 Q1	$207K	Buy	+2,253	New	+$194K	0.02%	562

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Zeke Capital Advisors's BPMC Position: Q3 2022 in Review

Zeke Capital Advisors sold out of Blueprint Medicines (BPMC) in Q3 2022, closing a stake of 5,023 shares — an estimated $254K sold.

Zeke Capital Advisors first reported a position in BPMC in Q1 2018 and held it in 15 quarters. The position peaked at $763K in Q4 2019. 240 funds tracked by Wall St. Rank hold BPMC as of Q3 2022.

Zeke Capital Advisors reported no remaining Blueprint Medicines position as of Q3 2022 after selling out during the quarter.
Zeke Capital Advisors sold 5,023 Blueprint Medicines shares in Q3 2022, an estimated $254K.
Zeke Capital Advisors first reported a position in Blueprint Medicines in Q1 2018 and held it in 15 quarters.
Zeke Capital Advisors's Blueprint Medicines position peaked at $763K in Q4 2019.
240 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2022.

Based on Zeke Capital Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.